HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

被引：0
|
作者：
Hearn, Jason W. D.
AbuAli, Ghada
Magi-Galluzzi, Cristina
Reddy, Chandana A.
Chang, Kai-Hsiung
Klein, Eric A.
Sharifi, Nima
机构：
[1] Cleveland Clin, Dept Radiat Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA
[4] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[5] Cleveland Clin, Dept Hematol & Oncol, Taussig Canc Inst, Cleveland, OH 44106 USA
[6] Cleveland Clin, Dept Canc Biol, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Cleveland Clin, Dept Urol, Taussig Canc Inst, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期
关键词：
D O I：
10.1200/jco.2015.33.7_suppl.156
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The association of germline HSD3B1 genotype with outcomes in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation therapy (ADT) with or without enzalutamide (ENZA) [ARCHES].
    Sharifi, Nima
    Azad, Arun
    Patel, Mona
    Hearn, Jason W. D.
    Wozniak, Michele
    Zohren, Fabian
    Sugg, Jennifer
    Haas, Gabriel P.
    Stenzl, Arnulf
    Armstrong, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Adrenal-Permissive Germline HSD3B1 Allele and Prostate Cancer Outcomes
    Mckay, Rana R.
    Nelson, Tyler J.
    Pagadala, Meghana S.
    Teerlink, Craig C.
    Gao, Anthony
    Bryant, Alex K.
    Agiri, Fatai Y.
    Guram, Kripa
    Thompson, Reid F.
    Pridgen, Kathryn M.
    Seibert, Tyler M.
    Lee, Kyung Min
    Carter, Hannah
    Lynch, Julie A.
    Hauger, Richard L.
    Rose, Brent S.
    JAMA NETWORK OPEN, 2024, 7 (03) : E242976
  • [33] Tumor cell intrinsic androgen biosynthesis by 3β-hydroxy steroid dehydrogenase (HSD3B1) to modulate radiosensitivity in prostate cancer cells
    Ganguly, Shinjini
    Balyimez, Aysegul
    Lone, Zaeem
    Hardaway, Aimalie
    Patel, Mona
    Davicioni, Elai
    Ornstein, Moshe Chaim
    Garcia, Jorge A.
    Stephans, Kevin L.
    Ciezki, Jay P.
    Tendulkar, Rahul D.
    Klein, Eric A.
    Sharifi, Nima
    Mian, Omar Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [34] Androgen deprivation therapy in prostate cancer. Indication and systemic consequences
    Rohayem, J.
    Kliesch, S.
    UROLOGE, 2012, 51 (04): : 557 - 564
  • [35] Reimbursement Policy and Androgen-Deprivation Therapy for Prostate Cancer.
    Shahinian, Vahakn B.
    Kuo, Yong-Fang
    Gilbert, Scott M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1822 - 1832
  • [36] Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility
    Chang, BL
    Zheng, SQL
    Hawkins, GA
    Isaacs, SD
    Wiley, KE
    Turner, A
    Carpten, JD
    Bleecker, ER
    Walsh, PC
    Trent, JM
    Meyers, DA
    Isaacs, WB
    Xu, JF
    CANCER RESEARCH, 2002, 62 (06) : 1784 - 1789
  • [37] Androgen deprivation therapy in advanced prostate cancer. Multicenter study
    Jose Valencia-Guadalajara, Victor
    Martinez-Cayuelas, Laura
    Sarrio-Sanz, Pau
    Sanchez-Caballero, Laura
    Polo-Hernandez, Rebeca
    Silvia Chillon-Sempere, Francisca
    Antonio Galan-Llopis, Juan
    Garces-Valverde, Marina
    Antonio Tenza-Tenza, Jose
    Costa-Martinez, Asuncion
    Garcia Serrado-Paumard, Diego
    Escudero-Fontana, Eva
    Tello-Royloa, Carlos
    Patricia Verdu-Verdu, Lidia
    Fernando Bravo-Lopez, Diego
    Perez Seoane-Ballester, Helena
    Jose Pacheco-Bru, Juan
    Angel Ortiz-Gorraiz, Manuel
    ARCHIVOS ESPANOLES DE UROLOGIA, 2020, 73 (06): : 499 - 508
  • [38] Outcomes of androgen deprivation as sole therapy for localized prostate cancer.
    Janoff, D
    Mongoue-Tchokote, S
    Peterson, C
    Parra, RO
    Peters, L
    Park, Y
    Beer, TM
    Mori, M
    Garzotto, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 413S - 413S
  • [39] HSD3B1 and overall survival (OS) in men with low-volume (LV) metastatic prostate cancer (PCa) treated with androgen deprivation therapy (ADT) or chemohormonal therapy in the CHAARTED Randomized trial.
    Hearn, Jason W. D.
    Sweeney, Christopher
    Almassi, Nima
    Reichard, Chad A.
    Reddy, Chandana A.
    Hobbs, Brian
    Jarrard, David Frazier
    Chen, Yu-Hui
    Dreicer, Robert
    Garcia, Jorge A.
    Carducci, Michael Anthony
    DiPaola, Robert S.
    Sharifi, Nima
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] AR Signaling in Prostate Cancer Regulates a Feed-Forward Mechanism of Androgen Synthesis by Way of HSD3B1 Upregulation
    Hettel, Daniel
    Zhang, Ao
    Alyamani, Mohammad
    Berk, Michael
    Sharifi, Nima
    ENDOCRINOLOGY, 2018, 159 (08) : 2884 - 2890
12345